JAZZJazz Pharmaceuticals plc

$12B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$666M+14.4% YoY

Gross Profit

$615M92.5% margin

Operating Income

$173M26.1% margin

Net Income

$133M20.0% margin

EPS (Diluted)

$2.33

QoQ Revenue Growth

+10.8%

Cash Flow

Operating Cash Flow

$186M

Free Cash Flow

$182M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$6.5B

Total Liabilities

$2.9B

Stockholders' Equity

$3.7B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$666M	$582M	+14.4%
Gross Profit	$615M	$546M	+12.6%
Operating Income	$173M	$61M	+183.1%
Net Income	$133M	$74M	+80.3%

Revenue Segments

Product And Services, Product Sales Net Of Deductions

$661M50%

Xyrem

$439M33%

Erwinaze And Erwinase

$57M4%

Defitelio/Defibrotide

$55M4%

Zepzelca

$53M4%

Vyxeos

$31M2%

Sunosi

$9M1%

Product And Services, Royalties And Contract Revenue

$4M0%

Other Products

$2M0%

Geographic Segments

UNITED STATES

$602M90%

Europe

$50M8%

Other Countries

$14M2%